Human Recombinant Interferon Gamma-1b for the Prevention of Hospital-acquired Pneumonia in Critically Ill Patients: a Double-blind, International, Phase 2, Randomized, Placebo-controlled Trial - the PREV-HAP Study
Conditions
Interventions
- DRUG: Recombinant Interferon gamma 1b (IMUKIN®)
- DRUG: Recombinant Interferon gamma 1b placebo
Sponsor
Nantes University Hospital